

TABLE 2

Knee pain on activity or rest, and changes for each group after treatment with hyaluronic acid (weeks 1, 5–7, 8–12, and 15–22)

	BASAL, MEAN (SD)		CHANGE AT 1 WEEK			CHANGE AT 5–7 WEEKS				CHANGE AT 8–12 WEEKS			CHANGE AT 15–22 WEEKS		
	Hyalgan, mean (SD)	Placebo, mean (SD)	Hyalgan mean	Placebo mean	Difference* mean (SE)	Hyalgan mean	Placebo mean	Difference* mean (SE)		Hyalgan mean	Placebo mean	Difference* mean (SE)	Hyalgan mean	Placebo mean	Difference* mean (SE)
Grecomoro	47 (22.4)	44 (21.2)	35	13	22 (6.7)	27	12	15 (6.5)							
Puhl	54.1 (22.6)	51.4 (22.4)	25.5	20	5.5 (3.2)	26.3	18.3	8 (3.2)		27.6	17.4	10.2 (3.2)			
Henderson 1	43.7 (7.8)	53.3 (7.2)	15.6	14.5	1.1 (2.4)										
Henderson 2	48.5 (5.5)	49.3 (6.2)	8.7	18	−9.3 (1.8)										
Scale	67 (8)	71 (6)	33	21	12 (2.7)	51	21	30 (2.7)		54	20	34 (2.7)			
Lohmander	44.4 (25.3)	42.31 (24.8)	12.5	16	−3.5 (3.6)					15	12	3 (3.6)	31.9 (25.5)	15.4 (24.8)	14.4 (3.6)
Altman	53 (29)	49 (29)	34	26.5	7.5 (3.9)	33	27	6 (3.8)		34	26.5	7.5 (3.8)	16.4 (29)	23.1 (29)	10.2 (3.9)
Wobig	71 (15)	75 (15.5)	40	22	18 (2.8)	47	15	32 (2.8)		48	14	34 (2.8)			
Huskisson	65.8 (18)	61.9 (22.9)	38.3	21.3	17 (5.2)	33.5	19.8	13.7 (5.4)		32.8	13.6	19.2 (5.7)	39.4 (27.8)	53.7 (29.9)	18.2 (5.5)
Petrella 1	3.3 (1.8)	3.3 (1.4)	2.6 (1.6)	1.8 (1.3)	−1.4 (0.5)										
Petrella 2	3.6 (1.9)	3.3 (1.4)	1.6 (1.3)	1.6 (1.3)	−0.2 (0.4)										

Pain measured on a visual analog scale of 100 mm at baseline. Scale and Wobig trials used hylan G-F20.

*Differences between groups of treatment were calculated by resting change in placebo group from change in hyalgan group. Standard error of this difference was imputed using the method of Follman et al.¹³